[go: up one dir, main page]

MX2009013676A - Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa. - Google Patents

Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa.

Info

Publication number
MX2009013676A
MX2009013676A MX2009013676A MX2009013676A MX2009013676A MX 2009013676 A MX2009013676 A MX 2009013676A MX 2009013676 A MX2009013676 A MX 2009013676A MX 2009013676 A MX2009013676 A MX 2009013676A MX 2009013676 A MX2009013676 A MX 2009013676A
Authority
MX
Mexico
Prior art keywords
methods
compositions
adenylyl cyclase
edema factor
inhibit edema
Prior art date
Application number
MX2009013676A
Other languages
English (en)
Inventor
Catherine H Schein
Deliang Chen
Scott Gilbertson
Maria Estrella-Jimenez
Jian Gao
Mary A Walter
Johnny W Peterson
Original Assignee
Mission Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40468705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009013676(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mission Pharma Co filed Critical Mission Pharma Co
Publication of MX2009013676A publication Critical patent/MX2009013676A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen moléculas pequeñas y sus derivados para el tratamiento y/o prevención de la pérdida de fluido intestinal. También se dan a conocer métodos para utilizar las moléculas y sus derivados para tratar y/o prevenir condiciones asociadas con los niveles incrementados de 3´,5´-adenosina monofosfato. También son novedosas las composiciones específicas de la invención.
MX2009013676A 2007-06-15 2008-06-13 Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa. MX2009013676A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94437507P 2007-06-15 2007-06-15
US3526908P 2008-03-10 2008-03-10
PCT/US2008/066898 WO2009038842A2 (en) 2007-06-15 2008-06-13 Methods and compositions to inhibit edema factor and adenylyl cyclase

Publications (1)

Publication Number Publication Date
MX2009013676A true MX2009013676A (es) 2010-06-01

Family

ID=40468705

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013676A MX2009013676A (es) 2007-06-15 2008-06-13 Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa.

Country Status (12)

Country Link
US (2) US8003692B2 (es)
EP (1) EP2166841A4 (es)
CN (1) CN101784274A (es)
AR (1) AR067850A1 (es)
AU (1) AU2008302667B2 (es)
BR (1) BRPI0813176A2 (es)
CA (1) CA2692004C (es)
CL (1) CL2008001782A1 (es)
CO (1) CO6270184A2 (es)
DO (1) DOP2009000272A (es)
MX (1) MX2009013676A (es)
WO (1) WO2009038842A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017681B2 (en) * 2007-01-12 2015-04-28 Cornell Research Foundation, Inc. Adenylyl cyclases as novel targets for antibactrial interventions
US9095578B2 (en) * 2007-01-12 2015-08-04 Cornell Research Foundation, Inc. Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens
MX2009013676A (es) * 2007-06-15 2010-06-01 Mission Pharma Co Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa.
EP2326953B1 (en) * 2008-07-22 2018-03-21 Promega Corporation Adp detection based luminescent phosphotransferase or atp hydrolase assay
CN102378753B (zh) 2009-03-31 2016-03-02 肾脏科学股份有限公司 纤溶酶原激活物抑制因子-1抑制剂
CN104159587A (zh) 2012-01-06 2014-11-19 南佛罗里达大学 组合物、使用方法、以及治疗方法
WO2014171464A1 (ja) 2013-04-15 2014-10-23 株式会社レナサイエンス Ｐａｉ－１阻害剤の新規用途
WO2016057084A1 (en) 2014-10-08 2016-04-14 Promega Corporation Bioluminescent succinate detection assay
CN105218343B (zh) * 2015-10-26 2017-03-22 乐普药业股份有限公司 一种3‑溴环己‑2‑烯‑1‑酮的合成方法
KR102672910B1 (ko) * 2017-01-10 2024-06-07 오웬-배리 파머소티컬즈 인코포레이티드 항경련 화합물
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
US10882821B1 (en) 2017-09-26 2021-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes
WO2019077631A1 (en) 2017-10-18 2019-04-25 Jubilant Biosys Limited IMIDAZO-PYRIDINE COMPOUNDS FOR USE AS PAD INHIBITORS
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
TWI904890B (zh) * 2024-10-14 2025-11-11 明志科技大學 鋅金屬有機框架材料及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066834A (en) 1974-01-24 1978-01-03 Miles Laboratories, Inc. Cycloalkenyl analogues of prostaglandins E
US4222944A (en) 1978-07-31 1980-09-16 Hoffmann-La Roche Inc. Halo-3-dibenzofuran alkanonitriles
JP2002514180A (ja) 1996-09-04 2002-05-14 ワーナー―ランバート・コンパニー マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法
CA2366877A1 (en) * 1999-03-22 2000-09-28 Stanley Michael Roberts Chemical compounds and their uses
CN1617716A (zh) 2000-06-08 2005-05-18 德克萨斯系统大学评议会 杂环衍生物与使用方法
WO2002040481A2 (en) * 2000-11-20 2002-05-23 Millennium Pharmaceuticals, Inc. Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions and method of use thereof
WO2002056879A1 (en) * 2001-01-03 2002-07-25 Medpharma Plc Use of terpenes for the treatment of digestive tract infections
DE10123163A1 (de) * 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituierte Cyclohexan-1,4-diaminderivate
WO2003016254A1 (en) * 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
JP2005511791A (ja) * 2001-12-14 2005-04-28 チャーターハウス セラピューティックス リミテッド 医薬組成物の改良
US20030157159A1 (en) * 2002-01-15 2003-08-21 Franklin Lanny Udell Prevention and treatment of digestive tract infections
US20030224403A1 (en) 2002-02-27 2003-12-04 Popov Serguei G. Lethal toxin cytopathogenicity and novel approaches to anthrax treatment
NZ531890A (en) * 2002-02-28 2006-02-24 Japan Tobacco Inc Ester compound and medicinal use thereof
PL376769A1 (pl) 2002-10-23 2006-01-09 Glenmark Pharmaceuticals Ltd. Nowe związki tricykliczne użyteczne w leczeniu chorób zapalnych i alergicznych, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające
WO2005005415A1 (en) * 2003-07-09 2005-01-20 Biolipox Ab Indoles useful in the treatment of inflammation
WO2005028467A1 (en) * 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
US7495103B2 (en) * 2004-06-24 2009-02-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2006039356A2 (en) * 2004-09-29 2006-04-13 Cytovia, Inc. Substituted n-aryl-9-oxo-9h-fluorene-1-carboxamides and analogs as activators of caspases and inducers of apoptosis
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
EP2029594B1 (en) * 2006-05-23 2010-10-20 NeuroSearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use
MX2009013676A (es) * 2007-06-15 2010-06-01 Mission Pharma Co Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa.

Also Published As

Publication number Publication date
AU2008302667B2 (en) 2014-07-10
US8003692B2 (en) 2011-08-23
WO2009038842A3 (en) 2009-12-30
AR067850A1 (es) 2009-10-28
US20120010233A1 (en) 2012-01-12
CO6270184A2 (es) 2011-04-20
CA2692004A1 (en) 2009-03-26
DOP2009000272A (es) 2010-02-15
EP2166841A2 (en) 2010-03-31
CN101784274A (zh) 2010-07-21
AU2008302667A1 (en) 2009-03-26
WO2009038842A2 (en) 2009-03-26
BRPI0813176A2 (pt) 2014-12-30
CA2692004C (en) 2013-04-09
CL2008001782A1 (es) 2008-11-03
EP2166841A4 (en) 2014-05-07
US20090093519A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
MX2009013676A (es) Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
UA99882C2 (uk) Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
MX2009009948A (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa.
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
EA200900571A1 (ru) Композиции chk1 ингибиторов
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
GT200800166A (es) Derivados de octahidro-pirrol (3,4-b) pirrol
MX2009011533A (es) Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
UA99924C2 (en) Benzylbenzol derivatives and using thereof
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
UA105390C2 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК

Legal Events

Date Code Title Description
FG Grant or registration